Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multicomponent Analysis of Liuwei Dihuang Pills by a Single Marker Quantification Method and Chemometric Discrimination of Fingerprints.

Journal of analytical methods in chemistry·2023
Same author

Circadian gene ARNTL initiates circGUCY1A2 transcription to suppress non-small cell lung cancer progression via miR-200c-3p/PTEN signaling.

Journal of experimental & clinical cancer research : CR·2023
Same author

Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation.

Bioscience reports·2023
Same author

Identifying prognostic markers in spatially heterogeneous breast cancer microenvironment.

Journal of translational medicine·2023
Same author

Water consumption of electric power system in China: from electricity generation to consumption.

Environmental science and pollution research international·2023
Same author

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.

Frontiers in immunology·2023

相关实验视频

Updated: Jul 17, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

生物标志物测试,治疗和患者的结果 晚期/转移性非小细胞肺癌 使用现实世界的数据库.

Naleen Raj Bhandari1, Lisa M Hess1, Dan He2

  • 1Eli Lilly and Company, Indianapolis, Indiana.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 6, 2023
PubMed
概括
此摘要是机器生成的。

在高级非小细胞肺癌 (a/mNSCLC) 中进行生物标志物测试可以提高生存率. 在生物标志物测试后,与指导方针一致的治疗与a/mNSCLC患者的更好的结果有关.

关键词:
生物标志物 生物标志物非小细胞肺癌的肺癌.总体存活率 总体存活率现实世界的电子医疗记录数据库.有针对性的治疗.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

相关实验视频

Last Updated: Jul 17, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

科学领域:

  • 在瘤学瘤学.
  • 生物标志物发现发现
  • 临床试验 临床试验

背景情况:

  • 对前期生物标志物测试对高级或转移性非小细胞肺癌 (a/mNSCLC) 的长期结果的影响的理解有限.
  • 现实世界的数据对于评估测试策略和治疗一致性至关重要.

研究的目的:

  • 根据生物标志物测试状态来比较总生存期 (OS).
  • 评估指导方针一致的治疗对a/mNSCLC患者的生存系统的影响.
  • 在a/mNSCLC中分析现实世界的数据,用于治疗决策.

主要方法:

  • 对一个大型现实世界 a/mNSCLC 电子医疗记录数据库的回顾性分析.
  • 包括从2015年1月1日起开始一线治疗的非皮质性a/mNSCLC患者.
  • 卡普兰-梅尔分析和多变量考克斯比例危险建模来比较OS.

主要成果:

  • 88%的患者至少记录了一项生物标志物测试;69%的患者在一线治疗开始前或开始时进行了测试.
  • 在从未测试过 (HR 1.30) 或在一线治疗前未测试过 (HR 1.12) 的患者中观察到更高的死亡风险.
  • 对于生物标志物阳性疾病患者,不接受符合指南的第一线治疗,死亡风险增加 (HR 1.25).

结论:

  • 前期生物标志物测试与a/mNSCLC的生存率改善有关.
  • 在生物标志物测试后,与指导方针一致的第一线治疗显著改善了生存结果.
  • 现实世界的证据支持将生物标志物测试纳入a/mNSCLC的治疗决策.